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Abstract
Triple negative breast cancer is typically an aggressive and difficult to treat subtype. It is
often associated with loss of function of the BRCA1 gene, either through mutation, loss of
heterozygosity or methylation. This study aimed to measure methylation of the BRCA1
gene promoter at individual CpG sites in blood, tumour and normal breast tissue, to assess
whether levels were correlated between different tissues, and with triple negative receptor
status, histopathological scoring for BRCA-like features and BRCA1 protein expression.
Blood DNA methylation levels were significantly correlated with tumour methylation at 9 of
11 CpG sites examined (p<0.0007). The levels of tumour DNAmethylation were signifi-
cantly higher in triple negative tumours, and in tumours with high BRCA-like histopatholog-
ical scores (10 of 11 CpG sites; p<0.01 and p<0.007 respectively). Similar results were
observed in blood DNA (6 of 11 CpG sites; p<0.03 and 7 of 11 CpG sites; p<0.02 respec-
tively). This study provides insight into the pattern of CpG methylation across the BRCA1
promoter, and supports previous studies suggesting that tumours with BRCA1 promoter
methylation have similar features to those with BRCA1mutations, and therefore may be
suitable for the same targeted therapies.
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Introduction
The triple negative (TN) subtype of breast cancer accounts for 10–17% of all breast carcinomas
[1–4]. Triple negative tumours are more likely to be of higher grade, to present with nodal or
distant metastases, and there is a relative lack of effective therapies compared to other cancer
subtypes, which all contribute to poor disease-free and overall survival [5]. By definition, these
tumours are oestrogen receptor (ER) and progesterone receptor (PR) negative and negative for
human epidermal growth factor receptor (HER2). Triple negative tumours are known to be a
heterogeneous group with a significant proportion displaying the basal-like phenotype; with
overexpression of cytokeratin 5/6(CK) and epidermal growth factor receptor (EGFR) proteins.
However, all other molecular subtypes of breast cancer are also present in TN cohorts [6, 7].
Recent comprehensive RNA and DNA profiling analyses have identified at least four distinct
subtypes of triple negative breast cancers that may have specific therapeutic targets based on
their molecular signatures [8, 9].
The Breast Cancer susceptibility gene 1 (BRCA1) is the most commonly mutated gene in
familial breast cancer cases and is strongly associated with both the TN subtype and basal-like
breast tumours [10, 11]. Over 50% of BRCA1mutation-associated tumours are TN [12], how-
ever, BRCA1mutations are rarely found in sporadic breast cancer cases and less than 15% of
TN tumours harbour BRCA1mutations [13–15]. The BRCA1 gene is involved in homologous
recombination DNA repair, which is the least error-prone mechanism for cells to repair dou-
ble-stranded DNA breaks [16]. Cells that lack functional BRCA1, whether it is through muta-
tion, loss of heterozygosity or epigenetic mechanisms, are deficient in homologous
recombination repair. These cells utilise alternative DNA repair mechanisms that are more
error prone, resulting in tumours with high levels of genomic instability [17, 18], a high fre-
quency of TP53 mutations [19] and numerous copy number aberrations [20]. These character-
istic patterns of gains and losses of genomic DNA associated with BRCA1mutant tumours can
be used to identify a larger group of sporadic cancers that are molecularly similar but lack
BRCA1mutations, known as BRCA1-like [20–22]. The term ‘BRCA-ness’ similarly refers to
tumours in which no germline BRCA1mutation has been identified but which share histopath-
ological features frequently found in BRCA1mutated tumours, including a high mitotic index,
pushing borders, syncytial and circumscribed growth patterns [23, 24].
There is considerable evidence that epigenetic mechanisms, in particular hypermethylation
of tumour suppressor gene promoters, represent an alternative method of gene silencing/ inac-
tivation [7, 24–26]. Methylation of the BRCA1 promoter in breast tumours is associated with a
poor overall survival and disease-free survival and has been suggested as a biomarker to guide
prognosis and targeted therapies [27–30]. Severson et al found that germline mutation and
BRCA1 promoter methylation overlap with BRCA1-like status (determined by copy number
aberrations) in 70% and 79% of their samples respectively [20]. Triple negative tumours in
young women with multiple BRCA1-like morphological features are associated with hyper-
methylation of the BRCA1 promoter in blood DNA [23]. However, there remains debate
regarding whether blood and tumour data are concordant for gene specific methylation [31].
Tumour BRCA1 promoter methylation has been reported to predict response to platinum
based chemotherapy agents and Poly(ADP-ribose) polymerase (PARP) inhibitors, therefore
methylation status could potentially influence treatment decisions [32].
In order to examine the relationship between BRCA1 promoter methylation, BRCA1 pro-
tein expression, triple negativity and BRCA1 associated histopathological features we have ana-
lysed blood samples from 658 women with sporadic breast cancer and 170 matched tumour
samples; 71 (11%) and 35 (21%) of these samples were classified as TN respectively.
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Methods
Study population and data collection
The study population comprised women diagnosed with invasive breast cancer at Sheffield
Teaching Hospitals NHS Foundation Trust, UK, recruited as part of the Sheffield Breast Can-
cer Study. The study was approved by the Sheffield Research Ethics Committee, and all women
provided written informed consent. Women were recruited in two cohorts between 1998–2008
and 2009–2014. Women in the earlier cohort were recruited from surgical outpatient clinics,
whilst women in the later cohort were newly diagnosed and recruited at pre-operative assess-
ment. Women with known BRCA1/2 gene mutations were excluded. Data on tumour grade,
receptor status, nodal status and age at diagnosis were obtained from clinical notes, and meno-
pausal status and family history of breast cancer were obtained from the patient by question-
naire administered by a research nurse. Samples from women with triple negative tumours
were preferentially selected for BRCA1 promoter methylation analysis.
Sample collection and DNA isolation
Genomic DNA was extracted from peripheral blood mononuclear cells isolated from 6ml
whole blood or 2ml ‘buffy coat’ samples according to the manufacturer’s protocol (Flexigene
DNA extraction kit, Qiagen). The concentration of extracted DNA was quantified using a
NanoDrop spectrophotometer (Thermo Scientific, ND-1000 software). DNA samples were
stored at -80°C until required. Tumour or normal tissue DNA was isolated following macrodis-
section from five 10 micron paraffin sections per FFPE block (to ensure greater than 80%
tumour cells), and extracted according to the manufacturer’s protocol (QIAamp DNA FFPE
kit, Qiagen). Tumour DNA was eluted in a final volume of 70μl buffer and then quantified
using a NanoDrop Spectrophotometer.
Receptor status
For the 1998–2008 cohort, tumour receptor status for ER, PR and HER2 were determined by
immunohistochemistry of triplicate tumour cores in tissue microarrays, and scored by SSC.
Antibodies were as follows; ER: Vector 6F11/2 (1:50), PR: Vector 1A6 (1:40), HER2: Dako Her-
cepTest Kit (pre-diluted). For the 2009–2014 cohort, ER and HER2 status determined accord-
ing to UK guidelines were obtained from NHS histopathology records.
Morphological scoring
Haematoxylin and Eosin (H&E) staining was performed on one slide per tumour and the slides
were systematically reviewed by a consultant histopathologist (SSC), who scored them for the
presence of nine BRCA1-associated morphological features; high mitotic index, malignant
nuclear grade, little or no (<10%) tubule formation, trabecular growth pattern, syncytial
growth pattern, pushing margins (>50%), circumscribed growth pattern, necrosis, moderate
or intense lymphocytic infiltrate [23, 33].
BRCA1 protein expression
BRCA1 immunohistochemistry was carried out using the anti-BRCA1 (Ab-1) mouse anti-
body (MS110 OP92 Calbiochem) on 5micron FFPE sections at 1:400 dilution as described
previously [36]. MCF-7 cell line cytospins were used to provide positive and negative (no pri-
mary antibody) controls. Slides were scored for BRCA1 nuclear staining by SSC and OW.
The percentage of positive nuclei were scored between 0 and 5, the intensity of nuclear stain-
ing was scored between 0 and 3, then these were added to form the combined score (Allred
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quick score). Tumours with a score equal or less than 4 were deemed to be negative for
BRCA1 expression.
Methylation analysis
Sodium-bisulphite modification of blood and tumour DNA was performed using the CpGe-
nome DNA modification kit (EMDMillipore, USA) according to the manufacturer’s proto-
col, to convert unmethylated cytosine residues to uracil. Sodium bisulphite-treated DNA was
then analysed by pyrosequencing as described previously [34]. Two sets of pyrosequencing
primers were designed for a 313 base pair (bp) region of the BRCA1 promoter using Pyro-
mark assay design software (version 2.0) and are detailed in Table 1. The pyrosequencing
targets contained 11 CpG sites, which included all of those studied by Wong et al plus two
additional adjacent sites (Fig 1) [23, 35]. CpG sites are referred to by their base pair position
relative to the BRCA1 transcription start site (position zero). The oligonucleotides (Sigma
Aldrich, Ebersberg, Germany) were reconstituted with deionised water at a stock concentra-
tion of 100pmol/μl.
PCR was performed using Hotstart taq DNA polymerase (Hotstart PCR kit, Qiagen) under
the following PCR conditions; denaturation at 95°C for 15 minutes followed by 50 cycles of the
following profile; 95°C for 20 seconds, 61°C for 20 seconds, 72°C for 20 seconds followed by a
final 5 minutes extension at 72°C. The PCR products were analysed by gel electrophoresis on a
1.5% Agarose gel stained with ethidium bromide and visualised by UV trans-illumination
prior to pyrosequencing. The 11 CpG sites were analysed by pyrosequencing using PyroMark
Q96 MD and Pyromark Gold reagents (Qiagen AG, Basel, Switzerland). Bisulphite-modified
universally methylated DNA (Chemicon International, NY) and distilled water were included
in each run as positive and negative controls.
Statistical Analysis
Correlation of methylation levels at individual CpG sites between matched tumour and
blood DNA, and between matched pairs of tumour samples was based on Spearman’s rank
correlation coefficient. Methylation levels between matched pairs of samples were com-
pared using the Wilcoxon matched-pairs signed-ranks test. Unmatched groups were com-
pared using the Mann-Whitney test. Associations between different pathological features
were assessed using contingency tables. The data set used for these analyses is provided in
S1 Table. All analyses were implemented in Stata V12.1 and all statistical tests were two-
sided.
Table 1. Details the primer sequences used for pyrosequencing.
5’3’ sequence Strand
Target region 1 F (Biotin)TGATTTAGTATTTTGAGAGGTTGTTGTT Sense
R CAATTATCTAAAAAACCCCACAACCTA Reverse
S CCCACAACCTATCCC Reverse
Target region 2 F GTATTTTTGAGAGGTTGTTGTT Sense
R (Biotin)AAACCCCACAACCTATCC Reverse
S TTTGAGAGGTTGTTGTTTA Sense
Primer orientation: Forward (F), Reverse (R), Sequencing (S).
doi:10.1371/journal.pone.0160174.t001
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Results
Baseline characteristics of cases and controls
Blood methylation analysis was successfully carried out on 658 cases, of whom 170 had suffi-
cient tumour tissue available for methylation analysis; 71 (11%) and 35 (21%) of these were
classified as TN respectively. Normal breast tissue was available for 26 cases, and for 20 cases
two tumour FFPE blocks were available from the same tumour. There were no significant dif-
ferences in baseline demographics (age, menopausal status and history of first degree relative
affected with breast cancer) between those from whom tumours were available and those
where only blood was available (Table 2). However, the cases where tumours were available
were of higher grade (p<0.001), more likely lymph node positive (p = 0.03) and more likely to
be TN (p<0.001) (Table 2), reflecting the fact that cases with TN disease were preferentially
selected for tumour analysis, and that tumours with sufficient tissue available for DNA extrac-
tion tend to be of higher grade and node positive since these features are associated with larger
tumours.
Methylation levels vary between CpG sites, and are higher in tumour
DNA compared to blood DNA
The levels of BRCA1 promoter methylation at 9 of the 11 CpG sites in blood DNA were found
to correlate with methylation at the corresponding sites in matched tumour DNA in the 170
cases for which both were available. Specifically, methylation levels at all sites apart from +27
and +44 were significantly correlated at p<0.0007 (Fig 2A and S2 Table). The levels of methyl-
ation were significantly higher in tumour DNA compared to matched blood DNA at all sites
apart from +16 (p<0.0025; Fig 2A and S2 Table). Blood DNAmethylation levels for subjects
with matched tumour (n = 170) were representative of the larger set of blood DNAmethylation
data (n = 658; Fig 2A). Furthermore, in both blood and tumour DNA there was a distinctive
pattern of methylation around the transcription start site, with higher levels of methylation
Fig 1. Diagram of the 11 CpG sites analysed by pyrosequencing. Individual CpG sites are underlined and numbering is relative to the BRCA1
Transcription Start Site (TSS). The start and end of the two overlapping target regions are detailed. No CpGs were present in the overlapping
section.
doi:10.1371/journal.pone.0160174.g001
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Number, n 658 488 170 20 26
Median age at diag
(range)
60 (23–92) 60 (23–92) 58 (24–85) p = 0.52 62.5 (24–84) 58.5 (39–84)
First degree relative
pos
119 (18.1%) 93 (19.1%) 26 (15.3%) 3 (15.0%) 4 (15.4%)
First degree relative
neg
539 (81.9%) 395 (81%) 144 (84.7%) 17 (85.0%) 22 (84.6%)
Total 658 488 170 p = 0.27 20 26
Pre/peri-
menopausal
177 (28.8%) 130 (28.6%) 47 (29.2%) 6 (31.6%) 8 (32%)
Post-menopausal 438 (71.2%) 324 (71.4%) 114 (70.8%) 13 (68.4%) 17 (68%)
Total 615 454 161 p = 0.89 19 25
Tumour grade 1 135 (21.8%) 112 (25%) 23 (14.6%) 0 (0%) 3 (12.0%)
Tumour grade 2 290 (46.8%) 224 (48.6%) 66 (41.8%) 12 (63.2%) 12 (48.0%)
Tumour grade 3 194 (31.3%) 125 (27.1%) 69 (43.7%) 7 (36.8%) 10 (40.0%)
Total 619 461 158 p<0.001 19 25
Lymph node
negative
385 (63.6%) 298 (66.1%) 87 (56.5%) 5 (27.8%) 14 (53.9%)
Lymph node
positive
220 (36.4%) 153 (33.9%) 67 (43.5%) 13 (72.2%) 12 (46.1%)
Total 605 451 154 p = 0.03 18 26
Non Triple Negative
(NTN)
585 (89.2%) 452 (92.6%) 133 (79.2%) 19 (95.0%) 22 (95.7%)
Triple Negative (TN) 71 (10.8%) 36 (7.4%) 35 (20.8%) 1 (5.0%) 1 (4.3%)
Total 656 488 168 p<0.001 20 23
Numbers for each sample group are given in each column. Cases with blood only are compared to cases with blood and tumour available.
doi:10.1371/journal.pone.0160174.t002
Fig 2. Methylation plots comparing blood, tumour and normal breast tissue.Mean (+/-SD) methylation levels plotted against CpG site
position along the chromosome in relation to the BRCA1 transcription start site (position zero). (A) Blood DNAmethylation level is shown in red and
tumour DNAmethylation level in blue for the matched samples (n = 170) and blood DNAmethylation level for the whole sample set is shown in
orange (n = 658). (B) Normal breast tissue DNAmethylation level is shown in green (n = 26) and tumour DNAmethylation level in blue (n = 170).
doi:10.1371/journal.pone.0160174.g002
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at -37 and -29 compared to the other sites (Fig 2A). DNA was available from normal breast tis-
sue for 26 cases. The BRCA1 promoter methylation levels were generally higher in tumour
DNA compared to normal breast tissue DNA, most significantly at -51, -21, -19 and +19
(p<0.03; Fig 2B and S2 Table). For 20 cases, two tumour FFPE blocks from the same tumour
were available. The methylation levels were significantly correlated between the pairs of blocks
for all CpG sites except -51 and +44 (p<0.04; S3 Table).
BRCA1-like morphological features are associated with triple negativity,
loss of BRCA1 protein expression and higher grade
We were able to score 147 tumours for the presence of 9 BRCA1-like morphological features
(Fig 3), and tumours were then grouped according to whether they exhibited five or more fea-
tures [33]. BRCA1 protein expression was assessed by immunohistochemistry in 119 cases (Fig
3). Higher levels of BRCA1 protein expression were associated with fewer BRCA1-like mor-
phological features (p = 0.019; Table 3). The number of morphological features was strongly
associated with triple negativity, larger tumour size and higher grade (p<0.0001, p = 0.034,
p<0.0001 respectively; Table 3).
Levels of both blood and tumour DNA methylation are higher in tumours
with high BRCA1-like features scores
The levels of tumour methylation were significantly higher in cases with tumours having more
than or equal to 5 BRCA1-like features compared to those with less than 5, at all CpG sites
except +44 (p = 0.007 to p<0.0001; Fig 4A and 4B and S4 Table). This pattern was also seen at
the majority of CpG sites in blood DNA, although the differences were less statistically signifi-
cant. Interestingly, the +27 CpG site was an exception, where the levels of blood methylation
were not significantly different in the group with over 5 BRCA1-like features compared to
those with fewer than 5 (p = 0.08 in blood, p<0.0001 in tumour; S4 Table)
Levels of both blood and tumour DNA methylation are higher in triple
negative tumours
Tumour DNA methylation was available for 35 triple-negative cases and 133 non-triple nega-
tive cases, and blood DNA methylation was available for 71 triple-negative and 585 non-triple
negative cases. The levels of both blood and tumour methylation were generally higher in triple
negative tumours compared to non-triple negative, at the majority of CpG sites apart from -51,
-29, +19 and +44 (p value range<0.0001 to 0.03 for blood DNA, and 0.0001 to 0.01 for tumour
DNA; Fig 4C and 4D and S5 Table). Again the +27 CpG site was the exception, with lower
methylation levels in blood DNA of TN cases compared to non-triple negative cases, in con-
trast to the higher levels in tumour DNA from TN cases (p = 0.0008 in blood and p = 0.0003 in
tumour; S5 Table).
Levels of tumour and blood methylation compared to BRCA1 protein
expression levels
There were 38 cases with high BRCA1 protein expression and 81 with low expression for
whom blood and tumour DNA methylation were available. There was no difference in blood
methylation levels at any CpG site between those with high or low levels of BRCA1 expression.
The levels of tumour DNAmethylation were generally higher in the samples with lower levels
of BRCA1 protein although the differences were not statistically significant (Fig 4E and 4F; S6
Table).
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Fig 3. Morphological features and BRCA1 expression.H&Es demonstrating BRCA1 associated morphological features scores. A: Low score
demonstrating good tubule formation, little nuclear pleomorphism, no lymphocytes and no mitoses. B: High score demonstrating syncytial islands, marked
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Discussion
BRCA1 promoter methylation may be used to guide therapy
Tumours arising in women with hereditary BRCA1mutations tend to be TN and basal-like,
features that are associated with a poor prognosis. However, in recent years it has become pos-
sible to exploit the DNA-repair defects in tumours carrying BRCA1 or BRCA2 gene mutations
using PARP inhibitors [37, 38]. The response of BRCA1mutation-associated cancers to both
PARP inhibitors and cisplatin-based chemotherapeutic agents has driven the interest in identi-
fying tumours with a similar DNA-repair deficient phenotype, so that these difficult to treat
patients might also benefit from targeted therapies. DNA methylation of the BRCA1 promoter
is a moderately frequent event in sporadic breast tumours and an alternative mechanism of
BRCA1 inactivation. In vitro studies suggest that cells with BRCA1 CpG island methylation are
also sensitive to PARP1 inhibitors and tumour BRCA1 promoter methylation predicts response
to platinum based chemotherapy agents and PARP inhibitors [32, 39, 40].
A recent meta-analysis of BRCA1 promoter methylation studies reported an association
between BRCA1methylation and BRCA-like clinico-pathological features such as lymph node
metastasis, histological grade 3, ER and PR negativity, triple-negative phenotype and decreased
BRCA1 protein expression [41]. However the majority of studies included in the meta-analysis
used methylation-specific PCR or other methods that do not distinguish individual CpG sites,
limiting mechanistic interpretation. Even a recent study of BRCA1 promoter methylation using
pyrosequencing analysed the results by averaging the methylation levels across all sites, thus
not utilizing the CpG site-specific results generated by pyrosequencing [42]. The considerable
heterogeneity between studies highlights the difficulties in drawing meaningful conclusions
when different CpG sites have been studied, methylation detection methods used, populations
studied and tissues examined [40]. In this study we have used pyrosequencing to distinguish
methylation levels at individual CpG sites in the BRCA1 promoter, and analysed CpG sites that
had been studied in at least three previous studies [23, 43, 44]. We have focused on obtaining a
comprehensive dataset consisting of methylation levels for blood and tumour DNA, BRCA1
protein expression, hormone receptor status, and morphological and clinico-pathological
features.
Blood and tumour methylation levels are related to BRCA-like
phenotypes
We found that there was a strong correlation between methylation levels in blood and tumour
DNA at all CpG sites apart from +27 and +44, with levels in the tumour being consistently
nuclear pleomorphism and heavy lymphocytic infiltrate. C, D&E: IHC performed using BRCA1 specific antibody Ab-1. C: Breast tumour demonstrating
nuclear staining for BRCA1. D: Breast tumour demonstrating lack of nuclear or cytoplasmic staining for BRCA1. E: Normal breast tissue demonstrating
normal nuclear staining for BRCA1. F: Histogram of the number of BRCA1-like morphological features from zero to 9 (n = 147).
doi:10.1371/journal.pone.0160174.g003
Table 3. Morphological feature scoring.
Number of morphological features (n) Mean age in years Median grade Mean size (mm) Number TN (%) BRCA1 expression (%positive)
5 (53) 57.0 2.8 25.4 26 (76.5) 9 (23.7)
<5 (94) 58.8 2.1 20.7 8 (23.5) 29 (76.3)
p = 0.41 p<0.0001 p = 0.034 p<0.0001 p = 0.019
Comparison of number of BRCA1-like morphological features with clinicopathological features; age, grade, size, TN receptor status and BRCA1 expression.
doi:10.1371/journal.pone.0160174.t003
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higher than those in the blood (or normal breast tissue), at all CpG sites. Whether the strong
correlation between these different tissues reflects independent events, constitutional changes
or global methylation changes secondary to carcinogenesis is beyond the scope of this study
due to its retrospective nature; prospective analyses are required to determine whether blood
methylation could be used as a predictor of tumour methylation [45, 46]. The effect of DNA
methylation on gene expression is complex with both hypo- and hypermethylation at specific
gene regions differentially affecting gene expression [47], however there is limited mechanistic
work on individual CpG sites.
Consistent with previous observations, we found that BRCA1-like morphological features
are correlated with triple negativity, loss of BRCA1 protein expression and higher grade. The
levels of both blood and tumour DNAmethylation at most CpG sites were higher in tumours
with high BRCA1-like features scores and were also higher in triple negative tumours, as was
shown by Wong et al [23]. The overall picture was that the associations in blood DNA were
weaker than those in tumour DNA but in the same direction. The +27 CpG site was an excep-
tion to this general pattern where the associations tended to be in the opposite direction in
blood and tumour DNA. We had limited power to detect associations with BRCA1 protein
expression, and although mean tumour DNAmethylation (at sites +8 to +44 in particular)
were higher in tumours with lower levels of BRCA1 protein, these effects did not reach statisti-
cal significance. Previous studies have shown a relationship between DNA methylation and
BRCA1 protein [24, 48, 49].
Other methylation analysis techniques more commonly used, including MSP (Methylation
Specific PCR), MS-HRM (methylation-sensitive high-resolution melting) Methyl-light and
MS-MLPA (methylation-specific multiplex ligation-dependent probe amplification) do not
give as much detailed information about the methylation status and often quintiles or arbitrary
cut off points are chosen to define ‘methylated’ or ‘unmethylated’ promoters. The meta-analy-
sis by Zhang et al found that over half of the studies included used MSP as their predominant
method for analysing methylation, whilst only one study used pyrosequencing [41, 50]. Meth-
ylation analysis using pyrosequencing is becoming widely used in diagnostics laboratories,
which may drive further translational research [51]. Future studies may need to focus on
appropriate methods of methylation analysis to detect levels in biopsy specimens, particularly
in TN tumours, because of the increasing use of neo-adjuvant chemotherapy.
The distribution of histopathological features, including receptor status, age at diagnosis
and grade, can be used to predict women more likely to harbour germline BRCA1 or BRCA2
mutations [52]. Scoring breast tumours for morphological features associated with ‘BRCAness’,
as has been performed in our study, can be used to help identify which tumours may have
higher levels of promoter methylation [23, 33]. This information could be used in future stud-
ies alongside receptor status, age at diagnosis and histological grade to select a subgroup of
patients for epigenetic and genetic testing and subsequent targeted therapies. The use of
tumour histopathology is gaining acceptance as a way to target costly and time-consuming
genetic testing to ‘at-risk’ individuals based on their tumour characteristics [53].
This study highlights the variability in methylation level at different CpG sites close to the
BRCA1 transcription start site. Methylation levels in tumour are generally greater than those in
blood, and methylation at most sites (apart from +27) increases in triple negative tumours and
Fig 4. Methylation plots comparing blood and tumour for BRCA1-like features, Triple negativity and BRCA1 protein expression.Mean (+/-SD)
methylation levels plotted against CpG site position along the chromosome in relation to the BRCA1 transcription start site (position zero). Blood
methylation level is shown on the left and tumour methylation level on the right. A&B: Tumours with <5 BRCA1-like features are shown in orange and those
with5 BRCA1-like features are shown in green. C&D: Triple negative tumours are shown in maroon and non-triple negative are shown in teal. E&F:
Tumours with high levels of BRCA1 protein expression are shown in brown and those with low levels are shown in cyan.
doi:10.1371/journal.pone.0160174.g004
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those with a high BRCA1-like features scores. Analysis of BRCA1 promoter methylation may
contribute to strategies for the identification of women who may benefit from PARP inhibition
or other targeted therapies, as has occurred in BRCA associated ovarian cancer [54].
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S1 Table. Data set used for analysis.
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S2 Table. Summary table comparing blood and tumour methylation at individual sites for
matched tumour and blood samples, the full cohort of blood samples and matched normal
and tumour tissue. The paired sign-rank tests have been used.
(XLSX)
S3 Table. Correlation of methylation levels between paired FFPE blocks from the same
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